Iovance Biotherapeutics, Inc. (IOVA)
| Market Cap | 1.89B +222.2% |
| Revenue (ttm) | 285.61M +34.3% |
| Net Income | -353.86M |
| EPS | -0.93 |
| Shares Out | 446.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,691,194 |
| Open | 4.500 |
| Previous Close | 4.380 |
| Day's Range | 4.170 - 4.560 |
| 52-Week Range | 1.660 - 5.630 |
| Beta | 0.70 |
| Analysts | Buy |
| Price Target | 8.80 (+108.04%) |
| Earnings Date | May 7, 2026 |
About IOVA
Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients w... [Read more]
Financial Performance
In 2025, Iovance Biotherapeutics's revenue was $263.50 million, an increase of 60.60% compared to the previous year's $164.07 million. Losses were -$390.98 million, 5.05% more than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for IOVA stock is "Buy." The 12-month stock price target is $8.8, which is an increase of 108.04% from the latest price.
News
Iovance Biotherapeutics Transcript: Jefferies Global Healthcare Conference 2026
AMTAGVI’s commercial launch is accelerating with strong U.S. and international uptake, backed by robust clinical data. The pipeline includes pivotal studies in melanoma, lung, endometrial, and sarcoma, with next-gen therapies advancing. 2024 revenue is guided at $350–$370M, and cash reserves should fund operations into 2028.
Iovance receives Australian approval of Amtagvi for advanced melanoma
Iovance Biotherapeutics (IOVA) announced that the Therapeutic Goods Administration of Australia has granted conditional approval of Amtagvi for previously treated advanced melanoma. Amtagvi is a tumor...
Iovance's Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy
Iovance gets allowance to proceed from FDA for IOV-5001 IND application
Iovance Biotherapeutics (IOVA) announced allowance to proceed from the FDA for the investigational new drug, or IND, application for a Phase 1/2 basket trial of IOV-5001, a next-generation interleukin...
Iovance Biotherapeutics Announces Clearance of Investigational New Drug (IND) Application for IL-12 Tethered TIL Therapy IOV-5001
Next-Generation Platform Expands into Solid Tumors Representing 100,000+ U.S. Deaths Annually SAN CARLOS, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a com...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and deliverin...
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi...
Iovance Biotherapeutics price target lowered to $14 from $16 at Chardan
Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $14 from $16 and keeps a Buy rating on the shares. The firm is adjusting its model to reflect…
Iovance Biotherapeutics reports Q1 EPS (19c), consensus (15c)
Reports Q1 revenue $71.43M, consensus $75.66M. Frederick Vogt, interim President and Chief Executive Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi ...
Iovance Biotherapeutics sees Q2 revenue $86M-$88M, consensus $84.36M
Sees Q2 Amtagvi revenue $79M-$81M.
Iovance Biotherapeutics sees FY26 revenue $350M-$370M, consensus $359.68M
08:11 EDT Iovance Biotherapeutics (IOVA) sees FY26 revenue $350M-$370M, consensus $359.68M
Iovance Biotherapeutics Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 45% year-over-year, driven by strong AMTAGVI demand and operational efficiencies. Guidance for Q2 and full-year 2026 remains robust, with margins expected to improve and a broadening pipeline targeting multiple solid tumor indications.
Iovance Biotherapeutics Earnings release: Q1 2026
Iovance Biotherapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Iovance Biotherapeutics Quarterly report: Q1 2026
Iovance Biotherapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
1Q26 Total Revenue of ~$71M Delivers ~ 45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial...
Iovance Biotherapeutics Proxy statement: Proxy filing
Iovance Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Iovance Biotherapeutics Proxy statement: Proxy filing
Iovance Biotherapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026
SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in...
Iovance Biotherapeutics Proxy statement: Proxy filing
Iovance Biotherapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Replimune CRL positive for Iovance in near-term, says Chardan
Chardan analyst Geulah Livshits keeps a Buy rating on Iovance Biotherapeutics (IOVA) with a $16 price target after Replimune (REPL) received a second complete response letter from the FDA for…
Iovance Biotherapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Three strategic pillars—commercial growth, pipeline expansion, and operational excellence—are driving strong momentum, with Amtagvi showing robust real-world efficacy and margin improvements. Pipeline advances in lung cancer, sarcoma, and next-gen TILs, plus global expansion, position the business for significant growth in 2026 and beyond.
Iovance Biotherapeutics price target raised to $4 from $2 at UBS
UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $2 and keeps a Neutral rating on the shares. Fundamentals improved in Q4, but…
Iovance Biotherapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Strong Q4 and full-year financials were driven by AMTAGVI adoption and operational improvements, with a focus on expanding treatment center networks and advancing a robust pipeline. Key clinical milestones are expected in lung cancer and sarcoma, with next-generation TIL therapies in development.
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf...
Iovance Biotherapeutics price target raised to $4 from $3 at Baird
Baird raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results…